Skip to content

Certolizumab pegol subcutaneous PK

A reduced subcutaneous PK model representing certolizumab pegol absorption from a depot, systemic elimination, blood concentration, and cumulative exposure.

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis ↗

Frontiers in Immunology

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

What does the loading regimen change after the first certolizumab dose?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

400 mg single-dose PBPK

How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?

0–14.125 day

Scenario details

400 mg single-dose PBPK

How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?

Readouts

Blood certolizumab concentration · Unit unavailable
Blood certolizumab concentration over the selected simulation window.
Exposure (AUC) · mg*day/L
Exposure (AUC) over the selected simulation window.
Apparent half-life · Unit unavailable
Apparent half-life over the selected simulation window.

Study purpose

  • How do loading and maintenance regimens shape certolizumab pegol blood concentration and exposure?

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Model parameter

Bioavailability represented as a dimensionless fraction in the released equations.

—

Suggested: 0.4–1.2. You can explore beyond this range.

0.8 → —

Effective distribution volume used to convert modeled amount to concentration in the relevant compartment.

L

Suggested: 1.91–5.73. You can explore beyond this range.

3.821 → —

Absorption rate constant governing entry from the administration site.

1/day

Suggested: 0.239–0.717. You can explore beyond this range.

0.4779 → —

Elimination rate constant governing first-order loss from the modeled system.

1/day

Suggested: 0.0321–0.0963. You can explore beyond this range.

0.06419 → —
Simulation time
day
day
14.13 → 168

Time between reported samples.

day
0.2 → 1

2 changes · Variation 1

Continue in the background and keep the result.

Biology

A subcutaneous certolizumab pegol dose enters a depot, is absorbed into a lumped blood compartment, undergoes first-order elimination, and contributes blood concentration to cumulative exposure.

How does subcutaneous certolizumab pegol reach blood and accumulate exposure?A subcutaneous certolizumab pegol dose enters a depot, is absorbed into a lumped blood compartment, undergoes first-order elimination, and contributes blood concentration to cumulative exposure.BIOLOGY OVERVIEWHow does subcutaneous certolizumab pegol reach blood and accumulate exposure?Subcutaneous dose: Certolizumab pegol inputSubcutaneous doseCertolizumab pegol inputSC depot: First-order absorption siteSC depotFirst-order absorption siteBlood exposure: Lumped systemic compartmentBlood exposureLumped systemic compartmentSystemic loss: First-order eliminationSystemic lossFirst-order eliminationCumulative exposure: Blood concentration integralCumulativeexposureBlood concentration integralPRIMARY READOUTSBlood certolizumab concentrationBlood certolizumab concent…Cumulative exposureCumulative exposureDerived half-lifeDerived half-life

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: TNF binding or inhibition, psoriasis immune biology, anatomical PBPK tissues, and a QSP network are outside this reduced one-compartment PK model.

Modeled relationships (4)
  • Subcutaneous dose → SC depot: SC input (flow)
  • SC depot → Blood exposure: F · ka (flow)
  • Blood exposure → Systemic loss: first-order (loss)
  • Blood exposure → Cumulative exposure: integrates C (production)

Modeled relationships: Subcutaneous dose to SC depot: SC input (flow); SC depot to Blood exposure: F · ka (flow); Blood exposure to Systemic loss: first-order (loss); Blood exposure to Cumulative exposure: integrates C (production).

Primary readouts: Blood certolizumab concentration; Cumulative exposure; Derived half-life.

Model details

4 parameters · 4 states · 4 equations · 8 derived outputs

Classification & API access
Therapeutic
Certolizumab pegol
Modality
Antibody fragment
Target
TNF / TNFA, P01375
Disease / scope
Plaque psoriasis
ParameterDefaultUnitDescription
Bioavailabilitybioavailability_fraction0.8—Bioavailability represented as a dimensionless fraction in the released equations.
Effective distribution volumeeffective_volume_l3.8209896068812603LEffective distribution volume used to convert modeled amount to concentration in the relevant compartment.
Absorption rate constantka_1_day0.477909240614491361/dayAbsorption rate constant governing entry from the administration site.
Elimination rate constantkel_1_day0.064188466639034631/dayElimination rate constant governing first-order loss from the modeled system.

Related models

Efalizumab reduced PASI progressionPROTAC target-engagement and degradation dynamics

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics